Clinical Trial Update: RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial evaluating RhGM-CSF as adjuvant immunotherapy for Stage III colon cancer, with the current status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• RhGM-CSF (sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor))

Snippet

Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Conditions: Colon Cancer | Phase 2 | Status: UNKNOWN